Integrative analysis of inhibitor of DNA-binding expression and prognosis in non-small cell lung cancer

Purpose: To investigate the expression and prognosis of inhibitor of DNA-binding (ID) protein family in non-small cell lung cancer (NSCLC). Methods: The mRNA expression and prognostic relevance of ID family using Oncomine, UALCAN, Kaplan-Meier plot, and The Cancer Genome Atlas (TCGA) databases were compiled and analyzed. Also, associations between individual IDs' mRNA expression and clinicopathological features in NSCLC patients were identified using unpaired t-test. Results: There was significantly higher expression of each ID in normal cells compared to NSCLC tissues, including adenocarcinoma (AC) and squamous cell carcinoma (SCC; p < 0.05). High ID1 mRNA expression correlated significantly with worse overall survival in NSCLC, AC, and SCC cases (p < 0.05). Also, increased ID4 mRNA expression predicted significantly better overall survival in NSCLC and AC cases, but not in SCC (p < 0.05). Conclusion: Inhibitor of DNA-binding 1 mRNA predicts poorer survival, whereas ID4 mRNA suggests better survival, particularly in AC. ID2 and ID3 mRNA levels lack significant associations with overall survival, suggesting targeting IDs might represent potential therapeutics for NSCLC. There is the need for validation of these outcomes and mechanistic investigations.